Table 2 Patients’ demographics, clinical characteristics, laboratory data, and imaging features of both groups
COVID-19 (n = 80) | Non-COVID-19 (n = 100) | P value | |
|---|---|---|---|
Age | 46.48 ± 16.09 | 48.94 ± 18.97 | 0.131 |
Sex | |||
Male | 49 (61.25%) | 55 (55%) | 0.108 |
Female | 31 (38.75%) | 45 (45%) | 0.098 |
Clinical data | |||
Fever | 72 (90%) | 62 (62%) | < 0.001 |
Cough and dyspnea | 65 (81.25%) | 85 (85%) | 0.218 |
GIT manifestations | 15 (18.75%) | 5 (5%) | < 0.001 |
Laboratory findings | |||
Leukocytosis | 12 (15%) | 56 (56%) | < 0.001 |
Lymphopenia | 44 (55%) | 21 (21%) | < 0.001 |
CT features | |||
Isolated GGO | 17 (21.5%) | 13 (13%) | 0.043 |
Consolidation | 54 (65%) | 72 (72%) | 0.268 |
Crazy-paving | 15 (18.75%) | 21 (21%) | 0.369 |
Reversed halo | 9 (11.25%) | 3 (3%) | 0.005 |
Subpleural bands | 24 (30%) | 19 (19%) | 0.048 |
Vascular thickening | 29 (36.25%) | 17 (17%) | 0.013 |
Traction bronchiectasis | 13 (16.25%) | 39 (39%) | 0.005 |
Pulmonary nodules | 17 (21.5%) | 41 (41%) | < 0.001 |
Lymphadenopathy | 0 (0%) | 12 (12%) | < 0.001 |
Pleural effusion | 4 (5%) | 32 (32%) | < 0.001 |
Laterality | |||
Unilateral | 12 (15%) | 19 (19%) | 0.323 |
Bilateral | 68 (85%) | 81 (81%) | 0.297 |
Lobar affection | |||
Upper | 43 (53.75%) | 67 (67%) | 0.039 |
Lower | 71 (88.75%) | 65 (65%) | 0.005 |
Distribution | |||
Peripheral | 63 (78.75%) | 46 (46%) | < 0.001 |
Central | 2 (2.5%) | 13 (13%) | < 0.001 |
Diffuse | 15 (18.75%) | 41 (41%) | < 0.001 |